Therapeutic controversy: The use of radioactive iodine in patients with papillary and follicular thyroid cancer

Journal of Clinical Endocrinology and Metabolism

Volumn 83, Issue 12, 1998, Pages 4195-4203

  Wartofsky, Leonard ^a  

^a WASHINGTON HOSPITAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCITONIN; FLUORODEOXYGLUCOSE F 18; IODINE 131; LEVOTHYROXINE; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; OXIDRONATE TECHNETIUM TC 99M; RADIOACTIVE IODINE; THYROGLOBULIN; THYROTROPIN I 125; THYROXINE DEIODINASE;

ARTICLE; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FOLLOW UP; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; THYROGLOBULIN BLOOD LEVEL; THYROID FOLLICULAR CARCINOMA; THYROID PAPILLARY CARCINOMA; THYROIDECTOMY; TREATMENT PLANNING; CHEMISTRY; REVIEW; THYROID TUMOR;

CARCINOMA, PAPILLARY, FOLLICULAR; HUMANS; IODINE RADIOISOTOPES; THYROGLOBULIN; THYROID NEOPLASMS;

EID: 0032238198     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.83.12.4195     Document Type: Article

References (42)

1. 1. Schlumberger MJ. 1998 Papillary and follicular thyroid carcinoma. N Engl J Med. 338:297-306.
2. 2. Singer PA, Cooper DS, Daniels GH, et al. 1996 Treatment guidelines for patients with thyroid nodules and well-differentiated thyroid cancer. Arch Intern Med. 156:2165-2172.
3. 3. Solomon BL, Wartofsky L, Burman KD. 1996 Current trends in the management of well differentiated papillary thyroid carcinoma. J Clin Endocrinol Metab. 81:333-339.
4. 4. Mazzaferri EL, Jhiang SM. 1994 Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med. 97:418-428.
5. 5. Samaan NA, Schultz PN, Hickey RC, et al. 1992 The results of various modalities of treatment of well differentiated thyroid carcinoma: a retrospective review of 1599 patients. J Clin Endocrinol Metab. 75:714-720.
6. 6. Hay ID, Bergstralh EJ, Goellner JR, Ebersold JR, Grant CS. 1993 Predicting outcome in papillary thyroid carcinoma: development of a reliable prognostic scoring system in a cohort of 1779 patients surgically treated at one institution during 1940 through 1989. Surgery. 114:1050-1058.
7. 7. Mazzaferri EL, Young RL, Oertel JE, Kammerer WT, Page CP. 1977 Papillary thyroid carcinoma: the impact of therapy in 576 patients. Medicine. 56:171-196.
8. 8. Simpson WJ, Panzarella T, Carruthers JS, Gospodarowicz MK, Sutcliffe SB. 1988 Papillary and follicular thyroid cancer: impact of treatment in 1578 patients. Int J Radiat Oncol Biol Phys. 14:1063-1075.
9. 9. Grant CS, Hay ID, Gogh IR, Bergstralh EJ, Goellner JR, McConahey WM. 1988 Local recurrence in papillary thyroid carcinoma: is extent of surgical resection important? Surgery. 104:954-962.
10. 10. Hay ID, Grant CS, Taylor WF, McConahey WM. 1987 Ipsilateral lobectromy vs. bilateral lobar resection in papillary thyroid carcinoma: a retrospective analysis of surgical outcome using a novel prognostic scoring system. Surgery. 102:1088-1095.
11. 11. Schlumberger M, Tubiana M, DeVathaire F, et al. 1986 Long-term results of treatment of 283 patients with lung and bone metastases from differentiated thyroid carcinoma. J Clin Endocrinol Metab. 63:960-967.
12. 12. Grant S, Luttrell B, Reeve T, et al. 1984 Thyroglobulin may be undetectable in the serum of patients with metastatic disease secondary to differentiated thyroid carcinoma. Follow-up of differentiated thyroid carcinoma. Cancer. 54:1625-1628.
13. 13. Casara D, Rubellow D, Saladini G, et al. 1993 Different features of pulmonary metastases in differentiated thyroid cancer: natural history and multivariate statistical analysis of prognostic variables. J Nucl Med. 34:1626-1631.
14. 14. Brendel AJ, Lamber B, Guyot M, et al. 1990 Low levels of serum thyroglobulin after withdrawal of thyroid suppression therapy in the follow-up of differentiated thyroid carcinoma. Eur J Nucl Med. 16:35-38.
15. 15. Spencer CA, Takeuchi M, Kazaroxyan M, et al. 1998 Serum thyroglobulin autoantibodies: prevalence, influence on serum thyroglobulin measurement, and prognostic significance in patients with differentiated thyroid carcinoma. J Clin Endocrinol Metab. 83:1121-1127.
16. 16. Park HM, Perkins OW, Edmondson JM, Schnute RB, Manatunga A. 1994 Influence of diagnostic radioiodine on the uptake of an ablative dose of iodine. Thyroid. 4:49-54.
17. 17. Ladenson PW, Braverman LE, Mazzaferri EL, et al. 1997 Comparison of administration of recombinant human thyrotropin with withdrawal of thyroid hormone for radioactive iodine scanning in patients with thyroid carcinoma. N Engl J Med. 337:888-896.
18. 131I and recombinant human thyroid stimulating hormone. J Clin Endocrinol Metab. 82:11-14.
19. 19. Gallowitsch HJ, Fellinger J, Mikosch P, Kresnik E, Lind P. 1997 Gamma probe-guided resection of a lymph node metastasis with I-123 in papillary thyroid carcinoma. Clin Nucl Med. 22:591-592.
20. 20. Boland GM, Lee MJ, Mueller PR, Mayo-Smith W, Dawson SL, Simeone JF. 1993 Efficacy of sonographically guided biopsy of thyroid masses and cervical lymph nodes. Am J Roentgenol. 161:1053-1056.
21. 21. Arturi F, Russo D, Giuffrida D, et al. 1997 Early diagnosis by genetic analysis of differentiated thyroid cancer metastases in small lymph nodes. J Clin Endocrinol Metab. 82:1638-1641.
22. 22. Pacini F, Fugazzola L, Lippi F, et al. 1992 Detection of thyroglobulin in fine needle aspirates of nonthyroidal neck masses: a clue to the diagnosis of metastatic differentiated thyroid cancer. J Clin Endocrinol Metab. 74:1401-1404.
23. 23. Maxon HR, Thomas SR, Boehringer A, et al. 1983 Low iodine diet in I-131 ablation of thyroid remnants. Clin Nucl Med. 8:123-126.
24. 131I therapy for elevated thyroglobulin levels. Thyroid. 7:273-276.
25. 25. Pineda JD, Lee T, Ain K, Reynolds J, Robbins J. 1995 Iodine-131 therapy for thyroid cancer patients with elevated thyroglobulin and negative diagnostic scan. J Clin Endocrinol Metab. 80:1488-1492.
26. 131I negative whole body scan, and positive thyroglobulin in differentiated thyroid carcinoma: what is being treated? Thyroid. 7:669-672.
27. 27. Mazzaferri EL. 1995 Editorial: Treating high thyroglobulin with radioiodine: a magic bullet or a shot in the dark? J Clin Endocrinol Metab. 80:1485-1487.
28. 28. Tubiana M, Haddad E, Schlumberger M, Hill C, Rougier P, Sarrazin D. 1985 External radiotherapy in thyroid cancers. Cancer. 55:2062-2071.
29. 29. Alam MS, Takeuchi R, Kasagi K, et al. 1997 Value of combined technetium-99 m hydroxy methylene diphosphonate and thallium-201 imaging in detecting bone metastases from thyroid carcinoma. Thyroid. 7:705-712.
30. 30. Carril JM, Quirce R, Serrano J, et al. 1997 Total body scintigraphy with thallium-201 and iodine-131 in the follow-up of differentiated thyroid cancer. J Nucl Med. 38:686-692.
31. 31. Dadparvar S, Chevres A, Tulchinsky M, et al. 1995 Clinical utility of technetium-99 m methoxisobutylisonitrile imaging in differentiated thyroid carcinoma: comparison with thallium-201 and iodine-131 scintigraphy and serum thyroglobulin quantitation. Eur J Nucl Med. 22:1330-1338.
32. 32. Lorberboym M, Murthy S, Mechanick JI, Bergman D, Morris JC, Kim CK. 1996 Thallium-201 and iodine-131 scintigraphy in differentiated thyroid carcinoma. J Nucl Med. 37:1487-1491.
33. 131I imaging in the follow-up of patients with well differentiated thyroid carcinoma. Nucl Med Commun. 17:373-377.
34. 34. Elser H, Henze M, Hermann C, Eckert W, Mende U. 1997 99m-Tc-MIBI for recurrent and metastatic differentiated thyroid carcinoma. Nuklearmedizin. 36:7-12.
35. 35. Lind P, Gallowitsch HJ. 1996 The use of non-specific tracers in the follow up of differentiated thyroid cancer: results with Tc-99 m tetrofosmin whole body scintigraphy. Acta Med Austr. 23:69-75.
36. 36. Gallowitsch HJ, Kresnik E, Mikosch P, Pipam W, Goez I, Lind P. 1996 Tc-99 m-tetrafosmin scintigraphy: an alternative scintigraphic method for following up differentiated thyroid carcinoma - preliminary results. Nuklearmedizin. 35:230-235.
37. 37. Lind P, Gallowitsch HJ, Langsteger W, Kresnik E, Mikosch P, Gomez I. 1997 Technetium-99m-tetrafosmin whole-body scintigraphy in the follow-up of differentiated thyroid carcinoma. J Nucl Med. 38:348-352.
38. 131Iodine and 99 m-Tc-sestamibi scintigraphy in differentiated thyroid cancer. Thyroid. 7:327-335.
39. 131I in patients with metastatic thyroid carcinoma. Nucl Med Commun. 18:3-9.
40. 40. Feine U, Lietzenmayer R, Hanke JP, Held J, Wohrle H, Muller-Schauenburg W. 1996 Fluorine-18-FDG and iodine-131 uptake in thyroid cancer. J Nucl Med. 37:1468-1472.
41. 41. Dietlein M, Scheidhauer K, Voth E, Theissen P, Schicha H. 1997 Fluorine-18 fluorodeoxyglucose positron emission tomography and iodine-131 whole-body scintigraphy in the follow-up of differentiated thyroid cancer. Eur J Nucl Med. 24:1342-1348.
42. 42. Baudin E, Schlumberger M, Lumbroso J, Travagli JP, Caillou B, Parmentier C. 1996 Octreotide scintigraphy in patients with differentiated thyroid carcinoma: contribution for patients with negative radioiodine scan. J Clin Endocrinol Metab. 81:2541-2544.